1. Home
  2. ACHV vs CTMX Comparison

ACHV vs CTMX Comparison

Compare ACHV & CTMX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Achieve Life Sciences Inc.

ACHV

Achieve Life Sciences Inc.

N/A

Current Price

$7.59

Market Cap

618.0M

Sector

Health Care

ML Signal

N/A

Logo CytomX Therapeutics Inc.

CTMX

CytomX Therapeutics Inc.

N/A

Current Price

$3.36

Market Cap

642.2M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
ACHV
CTMX
Founded
N/A
2008
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: In Vitro & In Vivo Diagnostic Substances
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
618.0M
642.2M
IPO Year
2018
2015

Fundamental Metrics

Financial Performance
Metric
ACHV
CTMX
Price
$7.59
$3.36
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
3
10
Target Price
$14.67
$12.10
AVG Volume (30 Days)
1.1M
2.6M
Earning Date
05-11-2026
05-08-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$76,201,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$7.61
P/E Ratio
N/A
$22.58
Revenue Growth
N/A
N/A
52 Week Low
$2.55
$1.89
52 Week High
$7.34
$8.21

Technical Indicators

Market Signals
Indicator
ACHV
CTMX
Relative Strength Index (RSI) 73.79 47.94
Support Level $4.04 $3.01
Resistance Level N/A $3.55
Average True Range (ATR) 0.33 0.15
MACD 0.08 0.02
Stochastic Oscillator 98.71 65.74

Price Performance

Historical Comparison
ACHV
CTMX

About ACHV Achieve Life Sciences Inc.

Achieve Life Sciences Inc is a late-stage clinical specialty pharmaceutical company with the sole mission to address the nicotine dependence epidemic through the development and commercialization of cytisinicline. Cytisinicline, is a naturally occurring alkaloid. Additionally, The company has completed a Phase 2 study with cytisinicline in vaping cessation and conducted a successful end-of-Phase 2 meeting with the FDA for a future vaping indication. It operates in one operating segment, development and commercialization of cytisinicline for nicotine dependence, with operations located in Canada, the United States and the U.K.

About CTMX CytomX Therapeutics Inc.

CytomX Therapeutics Inc a clinical-stage, oncology-focused biopharmaceutical company developing novel, masked, conditionally activated biologics designed to be localized to the tumor microenvironment. It is engaged in developing antibody therapeutics based on probody technology platforms. The company's probody technology platform creates proprietary cancer immunotherapies against clinically-validated targets and develops cancer therapeutics. Probody therapeutics are designed to take advantage of conditions in the tumor microenvironment to enhance the tumor-targeting features of an antibody and reduce drug activity in healthy tissues.

Share on Social Networks: